Community Use of Repurposed Drugs Before and During COVID-19 Pandemic in the Netherlands: An Interrupted Time-Series Analysis

References

• Smit M, Marinosci A, Agoritsas T, Calmy A. Prophylaxis for COVID-19: a systematic review. Clin Microbiol Infect. 2021;27(4):532–537. doi:10.1016/j.cmi.2021.01.013
   PubMed Web of Science ®Google Scholar
• Andrade BS, Rangel FDS, Santos NO, et al. Repurposing approved drugs for guiding COVID-19 prophylaxis: a systematic review. Front Pharmacol. 2020;11:590598. doi:10.3389/fphar.2020.590598
   PubMed Web of Science ®Google Scholar
• Bartoszko JJ, Siemieniuk RAC, Kum E, et al. Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ. 2021;373:1–12. doi:10.1136/bmj.n949
   Google Scholar
• Gouin KA, Creasy S, Beckerson M, et al. Trends in prescribing of antibiotics and drugs investigated for Coronavirus Disease 2019 (COVID-19) treatment in US nursing home residents during the COVID-19 pandemic. Clin Infect Dis. 2022;74(1):74–82. doi:10.1093/cid/ciab225
   PubMed Web of Science ®Google Scholar
• Schaffer AL, Henry D, Zoega H, Elliott JH, Pearson SA, Yon DK. Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID- 19 pandemic in Australia. PLoS One. 2022;17(6):1–13. doi:10.1371/journal.pone.0269482
   Web of Science ®Google Scholar
• Mian M, Sreedharan S, Giles S. Increased dispensing of prescription medications in Australia early in the COVID-19 pandemic. Med J Aust. 2021;214(9):428–429. doi:10.5694/mja2.51029
   PubMed Web of Science ®Google Scholar
• Hale T, Angrist N, Goldszmidt R, et al. A global panel database of pandemic policies (Oxford COVID-19 government response tracker). Nat Hum Behav. 2021;5(4):529–538. doi:10.1038/s41562-021-01079-8
   PubMed Web of Science ®Google Scholar
• Heins M, Hek K, Hooiveld M, Hendriksen J, Korevaar J. Impact Coronapandemie op Zorgvraag Bij Huisartsen (Factsheet A) (Impact of the Corona Pandemic on Care Demand at General Practitioners) . Nivel Accessed; 2021.
   Google Scholar
• Visser ST, Schuiling-Veninga CC, Bos JH, De Jong-Van Den Berg LT, Postma MJ. The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges. Expert Rev Pharmacoecon Outcomes Res. 2013;13(3):285–292. doi:10.1586/ERP.13.20
   PubMed Web of Science ®Google Scholar
• Pratt NL, Kerr M, Barratt JD, et al. The validity of the Rx-risk comorbidity index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) classification system. BMJ Open. 2018;8(4):e021122. doi:10.1136/BMJOPEN-2017-021122
   PubMed Web of Science ®Google Scholar
• Holvik K, Hjellvik V, Karlstad Ø, et al. Contribution of an extensive medication-based comorbidity index (Rx-Risk) in explaining the excess mortality after hip fracture in older Norwegians: a NOREPOS cohort study. BMJ Open. 2022;12(5):e057823. doi:10.1136/BMJOPEN-2021-057823
   PubMed Web of Science ®Google Scholar
• Daniels B, Tervonen HE, Pearson SA. Identifying incident cancer cases in dispensing claims: a validation study using Australia’s Repatriation Pharmaceutical Benefits Scheme (PBS) data. Int J Popul Data Sci. 2020;5(1):1152. doi:10.23889/ijpds.v5i1.1152
   Google Scholar
• Mathieu C, Pambrun E, Bénard-Laribière A, et al. Impact of the COVID-19 pandemic and its control measures on cardiovascular and antidiabetic drugs use in France in 2020: a nationwide repeated cohort study. Eur J Epidemiol. 2022;37(10):1049–1059. doi:10.1007/s10654-022-00912-2
   PubMed Web of Science ®Google Scholar
• Aboulatta L, Peymani P, Vaccaro C, et al. Drug utilization patterns before and during COVID-19 pandemic in Manitoba, Canada: a population-based study. PLoS One. 2022;17(11):1–15. doi:10.1371/journal.pone.0278072
   Web of Science ®Google Scholar
• Our World in Data. COVID-19: stringency index. Available from: https://ourworldindata.org/covid-stringency-index#citation. Accessed March 8, 2023.
   Google Scholar
• Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732–739. doi:10.1093/CID/CIAA237
   PubMed Web of Science ®Google Scholar
• Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. doi:10.1016/j.antiviral.2020.104787
   PubMed Web of Science ®Google Scholar
• Geller AI, Lovegrove MC, Lind JN, Datta SD, Budnitz DS. Assessment of outpatient dispensing of products proposed for treatment or prevention of COVID-19 by US retail pharmacies during the pandemic. JAMA Intern Med. 2021;181(6):869–872. doi:10.1001/JAMAINTERNMED.2021.0299
   PubMed Web of Science ®Google Scholar
• Lind JN, Lovegrove MC, Geller AI, Uyeki TM, Datta SD, Budnitz DS. Increase in outpatient ivermectin dispensing in the US during the COVID-19 pandemic: a cross-sectional analysis. J Gen Intern Med. 2021;36(9):2909–2911. doi:10.1007/s11606-021-06948-6
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials. Available from: https://www.ema.europa.eu/en/news/ema-advises-against-use-ivermectin-prevention-treatment-covid-19-outside-randomised-clinical-trials. Accessed March 22, 2021.
   Google Scholar
• Naggie S, Boulware DR, Lindsell CJ, et al. Effect of higher-dose ivermectin for 6 days vs placebo on time to sustained recovery in outpatients with COVID-19: a randomized clinical trial. JAMA. 2023;329(11):888–897. doi:10.1001/JAMA.2023.1650
   PubMed Web of Science ®Google Scholar
• Mouliou DS, Kotsiou OS, Gourgoulianis KI. Estimates of COVID-19 risk factors among social strata and predictors for a vulnerability to the infection. Int J Environ Res Public Health. 2021;18(16):8701. doi:10.3390/IJERPH18168701
   PubMed Web of Science ®Google Scholar
• van de Pol AC, Boeijen JA, Venekamp RP, et al. Impact of the covid-19 pandemic on antibiotic prescribing for common infections in the Netherlands: a primary care-based observational cohort study. Antibiotics. 2021;10(2):1–10. doi:10.3390/antibiotics10020196
   Google Scholar
• Hek K, Ramerman L, Weesie YM, et al. Antibiotic prescribing in Dutch daytime and out-of-hours general practice during the COVID-19 pandemic: a Retrospective Database Study. Antibiotics. 2022;11(3):309. doi:10.3390/antibiotics11030309
   Google Scholar
• Chalitsios CV, McKeever TM, Langley TE, Shaw DE. Impact of COVID-19 on corticosteroids and antibiotics prescribing in England: an interrupted time series analysis. J Public Health. 2021;43(3):517–520. doi:10.1093/pubmed/fdab017
   Google Scholar
• Gillies MB, Burgner DP, Ivancic L, et al. Changes in antibiotic prescribing following COVID-19 restrictions: lessons for post-pandemic antibiotic stewardship. Br J Clin Pharmacol. 2022;88(3):1143–1151. doi:10.1111/bcp.15000
   PubMed Web of Science ®Google Scholar
• Hernandez I, Gabriel N, He M, et al. COVID-19 and anticoagulation for atrial fibrillation: an analysis of US nationwide pharmacy claims data. J Am Heart Assoc. 2021;10(24). doi:10.1161/JAHA.121.023235
   Web of Science ®Google Scholar
• Antonazzo IC, Fornari C, Paoletti O, et al. COVID-19 outbreak impact on anticoagulants utilization: an interrupted time-series analysis using health care administrative databases. Thromb Haemost. 2021;121(8):1115–1118. doi:10.1055/a-1523-7658
   PubMedGoogle Scholar
• Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;181(12):1612–1620. doi:10.1001/JAMAINTERNMED.2021.6203
   PubMed Web of Science ®Google Scholar
• ATTACC, ACTIV-4a, and REMAP-CAP Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med. 2021;385(9):790–802. doi:10.1056/NEJMOA2105911
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757–767. doi:10.1016/S0140-6736(22)01429-5
   PubMed Web of Science ®Google Scholar
• Mouliou DS, Dardiotis E. Current evidence in SARS-CoV-2 mRNA vaccines and post-vaccination adverse reports: knowns and unknowns. Diagnostics. 2022;12(7):1555. doi:10.3390/DIAGNOSTICS12071555
   Web of Science ®Google Scholar
• Mouliou DS. The deceptive COVID-19: lessons from common molecular diagnostics and a novel plan for the prevention of the next pandemic. Diseases. 2023;11(1):20. doi:10.3390/DISEASES11010020
   PubMedGoogle Scholar